CNX-2006
目录号: A13755
EGFR 抑制剂
CNX-2006 是一种强效的、选择性的 EGFR 抑制剂，在具有激活性 EGFR 突变的细胞以及携带 T790M 突变的细胞中表现出优异的体外活性。CNX-2006 是 CO-1686 的原型，目前正在针对 EGFR 突变型肺癌的治疗进行第一阶段临床试验。
顾客使用 Adooq 产品发表的高质量科研文献
生物活性
| Discription | CNX-2006 is a potent, mutant-selective EGFR inhibitor with excellent in vitro activity in cells with activating EGFR mutations, as well as in cells harbouring the T790M mutation. CNX-2006 is the prototype for CO-1686, which is currently in a Phase I clinical trial for the treatment of EGFR-mutant lung cancer. | ||
|---|---|---|---|
| Targets |
|
产品信息
| 目录号 | A13755 |
|---|---|
| 分子式 | C26H27F4N7O2 |
| 分子量 | 545.53 |
| CAS号 | 1375465-09-0 |
| SMILES | COC1=C(C=CC(=C1)NC2CN(C2)CCF)NC3=NC=C(C(=N3)NC4=CC(=CC=C4)NC(=O)C=C)C(F)(F)F |
| 其他名称 | CNX2006, CNX 2006 |
| 储存条件 | Store lyophilized at -20ºC, keep desiccated. |
溶解性数据
| In vitro | DMSO | 90 mg/mL (164.97 mM) | |
| Water | Insoluble | ||
| Ethanol | 26 mg/mL (47.65 mM) | ||
|
* <1 mg/ml means slightly soluble or insoluble. * Please note that Adooq tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations. |
|||
Preparing Stock Solutions
| Concentration / Solvent Volume / Mass | 1 mg | 5 mg | 10 mg |
|---|---|---|---|
| 0.1 mM | 18.33 mL | 91.65 mL | 183.31 mL |
| 0.5 mM | 3.67 mL | 18.33 mL | 36.66 mL |
| 1 mM | 1.83 mL | 9.17 mL | 18.33 mL |
| 5 mM | 0.37 mL | 1.83 mL | 3.67 mL |
Useful Calculator
Calculate the dilution required to prepare a stock solution. This equation is commonly abbreviated as: C1V1 = C2V2
Keywords: 购买 CNX-2006 | CNX-2006 供应商 | CNX-2006 花费 | CNX-2006 生产商 | 订购 CNX-2006 | CNX-2006 代理商
| 购买 1375465-09-0 | 1375465-09-0 供应商 | 1375465-09-0 花费 | 1375465-09-0 生产商 | 订购 1375465-09-0 | 1375465-09-0 代理商